Drug intelligence / Profile preview

adebrelimab + cetuximab + chemotherapy

Development stage: Unknown
Lead developer: Hengrui Pharmaceutical
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous

Overview

This combination therapy consists of adebrelimab, cetuximab, and chemotherapy (either FOLFOX6 or FOLFIRI). Adebrelimab is a humanized IgG4 monoclonal antibody that targets programmed death-ligand 1 (PD-L1), developed by Jiangsu Hengrui Pharmaceuticals. Cetuximab is a chimeric monoclonal antibody targeting the epidermal growth factor receptor (EGFR). The combination is being investigated by The First Affiliated Hospital of Zhengzhou University in a Phase 2 clinical trial for the treatment of patients with RAS/BRAF wild-type unresectable liver metastases from colorectal cancer. The rationale for this regimen is to combine immune checkpoint inhibition with EGFR-targeted therapy and cytotoxic chemotherapy to improve conversion rates to resectability and overall survival in this specific molecular subset of colorectal cancer patients.

Brand names: AiruikaErbitux
Other names: adebrelimab + cetuximab + FOLFOX6adebrelimab + cetuximab + FOLFIRISHR-1316 + cetuximab + chemotherapy

Targets

TS (Thymidylate synthase)CD274 (Programmed cell death protein 1 ligand 1)TOP1 (DNA Topoisomerase I)DNAEGFR T790M (Epidermal growth factor receptor T790M mutant)

Beyond the preview

Go deeper on adebrelimab + cetuximab + chemotherapy.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on adebrelimab + cetuximab + chemotherapy.

Explore the full profile